- Total income
- ₹755 Cr
- Profit
- ₹73 Cr

About Bristol-Myers Squibb India Private Limited
Data last updated:
Bristol-Myers Squibb India Private Limited is a foreign private limited company based in Mumbai, Maharashtra, India, a subsidiary of Bms Pharmaceuticals International Holdings Netherlands B.V.. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 30 June 2004 and has been in existence for over 22 years.
Bristol-Myers Squibb India is ranked #395 on the Fortune MNC 500 India (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2004FTC147232. Its GSTIN is 27AACCB4313Q1ZI (Maharashtra). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹350 Cr and a paid-up capital of ₹346.91 Cr. It is led by directors including Sanjay Sharma and Raghavendra Agarwal.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at One International Center 6th Floor Tower 1 Senapati Bapat Marg Elphinstone (W), Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹881.76 Cr, a growth of 40% compared to the previous year. For the same year it recorded a net profit of ₹81.69 Cr (net margin 9.3%) and EBITDA of ₹128.15 Cr (EBITDA margin 14.5%). Revenue has grown at a compounded annual rate (CAGR) of 41% over three years and 21% over five years.
The company is associated with 1 brand: Bristol-Myers Squibb. Court records list 8 cases involving the company, including 2 filed by the company and 6 filed against it; 4 cases are pending. The company has 6 deals on record (5 funding rounds, 1 rights issue), with disclosed funding of ₹294.86 Cr; the latest was in October 2015. Its 4 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 1 smaller; the largest is Merck Specialities Private Limited with revenue of ₹1,027.41 Cr. The company has 8 MSME Form 1 returns on record between 2018 and 2024, listing 38 overdue payments to 12 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bms.com.
Company details
CIN history
Bristol-Myers Squibb India has one previous CIN (Corporate Identification Number): U24230MH2004PTC147232. The current CIN is U24230MH2004FTC147232, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230MH2004FTC147232 | Current |
| U24230MH2004PTC147232 | Previous |
Recognitions & Rankings of Bristol-Myers Squibb India
Contact details
Bristol-Myers Squibb India Private Limited's registered office is in Mumbai, Maharashtra. Its website is bms.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressOne International Center 6th Floor Tower 1 Senapati Bapat Marg Elphinstone (W), Mumbai, Maharashtra, India – 400013
- IndustryPharma, Pharmaceutical Retailers & Distributors, Pharma Contract R&D
To see the full contact details of Bristol-Myers Squibb India Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Bristol-Myers Squibb India operates one associated brand: Bristol-Myers Squibb. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | bms.com |
Business activity
The main business activity of Bristol-Myers Squibb India is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Bristol-Myers Squibb India Private Limited, buy the company report.
Financials of Bristol-Myers Squibb India Private Limited
FY 2025 filings availableBristol-Myers Squibb India Private Limited reported revenue of ₹881.76 Cr (up 40% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 21% over five years, including 40% growth in the latest year. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹881.76 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹128.15 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹81.69 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.5% | ||||
| Net Profit Margin | 9.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Bristol-Myers Squibb India Private Limited, buy the company report.
Board of directors of Bristol-Myers Squibb India Private Limited
Bristol-Myers Squibb India has 4 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sanjay Sharma | Director | 24 May 2022 | 4 Years 5 Months | Current |
| Raghavendra Agarwal | Director | 09 Oct 2014 | 12 Years 1 Months | Current |
| Harsh Atul Mehta | Director | 06 May 2025 | 1 Years 6 Months | Current |
| Anuradha Gupta | Director | 01 Apr 2025 | 1 Years 7 Months | Current |
Peer comparison
Bristol-Myers Squibb India Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Merck Specialities Private Limited | ₹1,027.41 Cr (FY 2025) | 13.0% | Mumbai, Maharashtra, India | |||
| Eli Lilly and Company (India ) Private Limited | ₹1,003.67 Cr (FY 2025) | 25.0% | Haryana, India | |||
| Neelkanth Drugs Private Limited | ₹897.65 Cr (FY 2023) | 38.0% | Hyderabad, Telangana, India | |||
| Bristol-Myers Squibb India Private Limitedthis company | ₹881.76 Cr (FY 2025) | ₹81.69 Cr | 9.3% | 40.0% | Mumbai, Maharashtra, India | |
| Meher Lifecare Private Limited | ₹789.83 Cr (FY 2025) | 10.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Bristol-Myers Squibb India Private Limited, buy the company report.
Auditor
Bristol-Myers Squibb India Private Limited is audited by Deloitte Haskins & Sells for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells | FY 2025 | 117366W/W-100018 |
Shareholding
The shareholding of Bristol-Myers Squibb India Private Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Bristol-Myers Squibb India Private Limited, buy the company report.
Deals & funding
Bristol-Myers Squibb India Private Limited has 6 deals on record (5 funding rounds, 1 rights issue), with disclosed funding of ₹294.86 Cr; the latest was in October 2015.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2015 | Rights issue | ₹52 Cr | Investors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV |
| Dec 2014 | Funding round | ₹48 Cr | Investors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV |
| Mar 2013 | Funding round | ₹148.04 Cr | Investors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV |
| Feb 2012 | Funding round | ₹52.05 Cr | Investors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV |
| Oct 2009 | Funding round | ₹23.86 Cr | Investors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV |
To see the full deal history of Bristol-Myers Squibb India Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Bristol-Myers Squibb India Private Limited has 8 court cases on record: 2 filed by Bristol-Myers Squibb India, 6 filed against it. 4 cases are pending and 4 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 4 | 4 |
| Supreme Court | 2 | 2 | 0 |
Cases on record (5 of 8)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (-Ordinary Civil Matters) | Filed against the company by M/S Accure Labs Pvt. Ltd. Authorised Representative Ms. Mukti Swarup Flat No. 1406A, 14Th Floor, Building No. 89, Hemkunth Chamber, Nehru Place ,New Delhi , Delhi | Disposed |
| High Court, GUJARAT | Special civil application | Filed by the company against Bristal Life Science Private Limited and 1 other | Disposed |
| Supreme Court | Court case (1802-Ordinary Civil Matters : T.P. Under Section 25 of the C.P.C.) | Filed against the company by Natco Pharma Limited Authorised Signatory Rohit Kumar Goyal Natco House Road No 2, Banjara Hills, ,Hyderabad , Telangana | Disposed |
| High Court | Tax appeal | Filed against the company by Prinicipal Commissioner of Income Tax 6 Mumbai | Pending |
| Bombay High Court | Tax appeal | Filed against the company by PR Commissioner of Income Tax 6 | Pending |
To see the full case history of Bristol-Myers Squibb India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Bristol-Myers Squibb India Private Limited has 8 MSME Form 1 returns on record between 2018 and 2024, listing 38 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 12)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| S K Logistics | |||
| an individual supplier | |||
| Zenith Leisure Holidays Limited | |||
| Artiligence Private Limited | |||
| S K Lotlikar and Co |
To see the full MSME payment records of Bristol-Myers Squibb India Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Bristol-Myers Squibb India has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCB4313Q1ZI | Maharashtra | Active | 01 Jul 2017 |
| 07AACCB4313Q1ZK | Delhi | Active | 01 Jul 2017 |
| 29AACCB4313Q1ZE | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Bristol-Myers Squibb India Private Limited, buy the company report.
Recent activity
Bristol-Myers Squibb India Private Limited has 23 board changes on record since 2008: 4 appointments and 19 cessations. The latest: Anuradha Gupta ceased to be Additional Director on 21 Sep 2025.
14 earlier events are in the company report.
News
Frequently asked questions
Bristol-Myers Squibb India is an active foreign private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 30 June 2004 (22+ years old) and is registered under CIN U24230MH2004FTC147232.
Bristol-Myers Squibb India has 4 current directors:
- Sanjay Sharma - Director
- Raghavendra Agarwal - Director
- Harsh Atul Mehta - Director
- Anuradha Gupta - Director
The latest financial statements of Bristol-Myers Squibb India on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Bristol-Myers Squibb India is 27AACCB4313Q1ZI, registered in Maharashtra. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 07AACCB4313Q1ZK (Delhi), 29AACCB4313Q1ZE (Karnataka).
The CIN (Corporate Identification Number) of Bristol-Myers Squibb India is U24230MH2004FTC147232. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Bristol-Myers Squibb India has 8 court cases on record: 2 filed by the company and 6 filed against it. 4 are pending. Most are in the high courts.
Bristol-Myers Squibb India was incorporated on 30 June 2004, making it 22+ years old. It is registered with the Registrar of Companies, Mumbai.
Bristol-Myers Squibb India has 6 deals on record (5 funding rounds, 1 rights issue), with disclosed funding of ₹294.86 Cr; the latest was in October 2015.
The peers of Bristol-Myers Squibb India by revenue are Merck Specialities Private Limited, Eli Lilly and Company (India ) Private Limited, Neelkanth Drugs Private Limited, Meher Lifecare Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Anuradha Gupta ceased to be Additional Director on 21 Sep 2025. Harsh Atul Mehta ceased to be Additional Director on 21 Sep 2025. Harsh Atul Mehta was appointed as Director on 06 May 2025. Bristol-Myers Squibb India has 23 board changes on record in total.
Bristol-Myers Squibb India has 8 MSME Form 1 returns on record between 2018 and 2024, listing 38 overdue payments to 12 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Bristol-Myers Squibb India can be reached through the website bms.com. Its registered office is in Mumbai, Maharashtra, India.

